DelveInsight’s, “Irritable Bowel Syndrome Pipeline Insight, 2023,” report provides comprehensive insights about 24+ companies and 24+ pipeline drugs in Irritable Bowel Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Irritable Bowel Syndrome pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

For Irritable Bowel Syndrome Emerging drugs, the Irritable Bowel Syndrome pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The Irritable Bowel Syndrome pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

 

In the Irritable Bowel Syndrome Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, Irritable Bowel Syndrome clinical trials studies, Irritable Bowel Syndrome NDA approvals (if any), and product development activities comprising the technology, Irritable Bowel Syndrome collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

 

Key takeaways from the Irritable Bowel Syndrome Pipeline Report

 

• DelveInsight’s irritable bowel syndrome pipeline report depicts a robust space with 24+ companies and 24+ pipeline drugs for irritable bowel syndrome treatment.

 

• The leading Irritable Bowel Syndrome Companies include Arena Pharmaceuticals, 4D Pharma, OrphoMed, Boston Pharmaceuticals, RedHill Biopharma Limited, Takeda, Cosmo Technologies, CinRx Pharma, Rottapharm, Synthetic Biologics, Biomica, Metacrine, MGC Pharma, Napo Pharmaceuticals, Novome Biotechnologies, Renexxion, Sentia Medical Sciences, Serentrix LLC, Vitality Biopharma, and others

 

• Promising Irritable Bowel Syndrome Pipeline Therapies includes Olorinab, Blautix, ORP-101, BOS-589, BEKINDA, Rifamycin controlled-release, CIN 103, Crofelemer, RQ-00310941, AAT 730, and others.

 

• The Irritable Bowel Syndrome companies and academics are working to assess challenges and seek opportunities that could influence Irritable bowel syndrome R&D. The Irritable Bowel Syndrome pipeline therapies under development are focused on novel approaches to treat/improve Irritable bowel syndrome.

 

Request a sample and discover the recent breakthroughs happening in the Irritable Bowel Syndrome Pipeline landscape @ Irritable Bowel Syndrome Pipeline Outlook Report

 

Irritable Bowel Syndrome Overview

Irritable bowel syndrome (IBS) is a group of symptoms that occur together, including repeated pain in your abdomen and changes in your bowel movements, which may be diarrhea, constipation, or both. With IBS, you have these symptoms without any visible signs of damage or disease in your digestive tract. The most common symptoms of irritable bowel syndrome (IBS) are pain in your abdomen, often related to your bowel movements, and changes in your bowel movements.

 

Recent Developmental Activities in the Irritable Bowel Syndrome Treatment Landscape

 

• In October 2022, Intrinsic Medicine and Phoenix Biotech Acquisition Corp. announced they have entered into a definitive business combination agreement.

 

• In September 2022, Novome Biotechnologies, Inc., a biotechnology company engineering first-in-class, living medicines for chronic diseases, announced the closing of a $43.5 million Series B financing. 

 

For further information, refer to the detailed Irritable Bowel Syndrome Drugs Launch, Myo Irritable Bowel Syndrome Developmental Activities, and Irritable Bowel Syndrome News, click here for Irritable Bowel Syndrome Ongoing Clinical Trial Analysis

 

Irritable Bowel Syndrome Emerging Drugs Profile

 

• ORP-101: OrphoMed

ORP-101 is a new chemical entity designed to confer peripheral partial μ agonist and full κ receptor antagonist activity, enabling treatment of both IBS-D symptoms of dysmotility and pain without the risk of sphincter of Oddi spasm or pancreatitis. ORP-101 has been shown in preclinical studies to not cross the blood-brain barrier. ORP-101 successfully completed Phase 1 clinical trials and was granted FDA Fast Track designation in 2018. Regulatory path to NDA has been agreed with the FDA. Currently, it is in Phase II stage of clinical trial evaluation to treat Irritable bowel syndrome. 

 

• Blautix: 4D Pharma

Blautix® is a single strain Live Biotherapeutic product (LBP), being developed as a treatment for both IBS-C and IBS-D. Pre-clinical studies demonstrated its ability to address visceral hypersensitivity and other symptoms of IBS and increase microbiome diversity. A Phase I study in healthy volunteers and IBS patients showed that Blautix® was well tolerated and an improvement in symptoms was also reported relative to placebo. The Phase II BHT-II-002 trial demonstrated an impact on overall response with regards to bowel habit and abdominal pain in IBS-C and IBS-D. Blautix® was well tolerated, with a safety profile comparable to placebo.

 

Irritable Bowel Syndrome Pipeline Therapeutics Assessment

There are approx. 24+ key companies which are developing the therapies for Irritable bowel syndrome. The companies which have their Irritable bowel syndrome drug candidates in the most advanced stage, i.e. phase II include OrphoMed.

 

Find out more about the Irritable Bowel Syndrome Pipeline Segmentation, Therapeutics Assessment, and Irritable Bowel Syndrome Emerging Drugs @ Irritable Bowel Syndrome Treatment Landscape

 

Scope of the Irritable Bowel Syndrome Pipeline Report

 

• Coverage- Global

 

• Irritable Bowel Syndrome Companies- Arena Pharmaceuticals, 4D Pharma, OrphoMed, Boston Pharmaceuticals, RedHill Biopharma Limited, Takeda, Cosmo Technologies, CinRx Pharma, Rottapharm, Synthetic Biologics, Biomica, Metacrine, MGC Pharma, Napo Pharmaceuticals, Novome Biotechnologies, Renexxion, Sentia Medical Sciences, Serentrix LLC, Vitality Biopharma, and others.

 

• Irritable Bowel Syndrome Pipeline Therapies- Olorinab, Blautix, ORP-101, BOS-589, BEKINDA, Rifamycin controlled-release, CIN 103, Crofelemer, RQ-00310941, AAT 730, and others.

 

• Irritable Bowel Syndrome Pipeline Segmentation: Product Type, Molecule Type, Mechanism of Action, Route of Administration

 

Dive deep into rich insights for drugs for Irritable Bowel Syndrome Pipeline Companies and Therapies, click here @ Irritable Bowel Syndrome Unmet Needs and Analyst Views

 

Table of Content

1. Introduction
2. Executive Summary
3. Irritable bowel syndrome: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Irritable bowel syndrome – DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Drug name: Company name
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. ORP-101: OrphoMed
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. Drug name: Company name
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Irritable bowel syndrome Key Companies
21. Irritable bowel syndrome Key Products
22. Irritable bowel syndrome- Unmet Needs
23. Irritable bowel syndrome- Market Drivers and Barriers
24. Irritable bowel syndrome- Future Perspectives and Conclusion
25. Irritable bowel syndrome Analyst Views
26. Irritable bowel syndrome Key Companies
27. Appendix

 

Got Queries? Find out the related information on Irritable Bowel Syndrome Mergers and acquisitions, Irritable Bowel Syndrome Licensing Activities @ Irritable Bowel Syndrome Recent Trends, and Future Perspectives

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/